Mankind Pharma

2,350.50
+36.55
(1.58%)
Market Cap
96,976.58 Cr
EPS
47.75
PE Ratio
46.77
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
1,901.05
PB Ratio
7.04
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from14 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+71.43 %
+71.43 %
Hold
Hold+14.29 %
+14.29 %
Sell
Sell+14.29 %
+14.29 %

Company News

View All News
Caret
positive
Mankind Pharma Announces Corporate Restructuring and Expansion Plans12 hours ago
Mankind Pharma has announced several strategic moves: 1) The company will incorporate a wholly owned subsidiary in Russia, indicating international expansion. 2) A new wholly owned subsidiary will be established for CSR activities, demonstrating a focus on corporate social responsibility. 3) The board has approved the formation of a committee to integrate Bharat Serums and Vaccines, suggesting potential merger or acquisition activities.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
#5 96,976.58
#8 46.77
#8 10,615.60
#2 19.57
#6 1,942
#10 -16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
19.57 %
Net Income Growth
48.26 %
Cash Flow Change
18.70 %
ROE
18.04 %
ROCE
13.14 %
EBITDA Margin (Avg.)
16.05 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,536
2,998
3,189
3,311
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,850
2,212
2,227
2,400
EBITDA
323
476
622
477
467
718
746
681
686
786
962
911
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
24 %
28 %
26 %
Depreciation
47
78
79
85
85
87
97
110
105
108
106
192
Interest
13
16
10
13
5
6
9
9
9
11
7
221
Profit Before Tax
263
382
533
379
377
625
641
562
572
668
849
497
Tax
70
84
110
83
84
130
130
103
95
125
190
113
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.45

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
9,148
9,715
11,963
Fixed Assets
3,588
4,251
4,545
Current Assets
4,407
4,328
6,568
Capital Work in Progress
702
550
282
Investments
1,110
1,346
2,568
Other Assets
3,749
3,568
4,568
Total Liabilities
9,148
9,715
11,963
Current Liabilities
2,624
1,863
2,120
Non Current Liabilities
208
229
268
Total Equity
6,316
7,623
9,576
Reserve & Surplus
6,115
7,395
9,323
Share Capital
40
40
40

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
103
-92
156
22
77
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
Operating Activities
1,070
1,137
920
1,813
2,152
Financing Activities
-531
-8
605
-740
5

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Acquisition13 hours ago
Board Meeting Outcome for Outcome Of Board Meeting Held On April 14 202513 hours ago
Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017) 3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMar 29, 2025
Effective Date Of The Scheme Of Arrangement For Amalgamation Amongst Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedMar 29, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementMar 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 25, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedFeb 27, 2025
Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedFeb 27, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 25, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 18, 2025
Final Update On Stake Sale Of Mahananda Spa And Resorts Private LimitedFeb 11, 2025
Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentFeb 10, 2025
Board Meeting Outcome for Mankind Pharma Limited Has Informed The Exchange Regarding Sale Of Entire Stake In Mahananda Spa And Resorts Private LimitedFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 04, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJan 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2025
Statement Under Regulation 32 Of The Listing Regulations.Jan 23, 2025
Integrated Filing (Financial)Jan 23, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 23 2025.Jan 23, 2025
Intimation Regarding Redemption Of Commercial PaperJan 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Commercial Paper-Quarterly Certificate December 2024Jan 14, 2025
Intimation Of Record Date For Redemption Of Commercial Paper Issued By The CompanyJan 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 14, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 13, 2025
Announcement Under Regulation 30 Of SEBI LODRJan 08, 2025
Appointment of Company Secretary and Compliance OfficerJan 08, 2025
Announcement under Regulation 30 (LODR)-CessationJan 08, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. January 8 2025Jan 08, 2025
Creation Of Pledge On The Shares Of Bharat Serums And Vaccines LimitedJan 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) 2015Dec 28, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 27, 2024

Technical Indicators

RSI(14)
Neutral
48.68
ATR(14)
Less Volatile
88.87
STOCH(9,6)
Neutral
31.85
STOCH RSI(14)
Neutral
28.76
MACD(12,26)
Bullish
0.64
ADX(14)
Weak Trend
22.93
UO(9)
Bearish
40.46
ROC(12)
Downtrend And Accelerating
-0.91
WillR(14)
Neutral
-64.80

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(1 Years, 37 days)
Chairperson NameRAMESH CHAND JUNEJA